NEW YORK (GenomeWeb News) – Ventana Medical Systems and Syndax Pharmaceuticals have signed an agreement for the development of a companion diagnostic for a drug being developed by Syndax to treat non-small cell lung cancer patients.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.